NuVasive, Inc.  

(Public, NASDAQ:NUVA)   Watch this stock  
Find more results for Mike Farrell
46.32
-0.98 (-2.07%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 45.92 - 47.44
52 week 31.35 - 51.23
Open 46.85
Vol / Avg. 473,613.00/358,122.00
Mkt cap 2.18B
P/E     -
Div/yield     -
EPS -0.40
Shares 47.04M
Beta 1.20
Inst. own 103%
Feb 24, 2015
Q4 2014 NuVasive Inc Earnings Call - 5:30PM EST - Add to calendar
Feb 24, 2015
Q4 2014 NuVasive Inc Earnings Release - 4:00PM EST - Add to calendar
Jan 14, 2015
NuVasive�, Inc. at the 33rd Annual J.P. Morgan Healthcare Conference - Webcast
Jan 12, 2015
Preliminary 2014 NuVasive Inc Earnings Release
Dec 2, 2014
NuVasive Inc at Piper Jaffray Healthcare Conference
Nov 13, 2014
NuVasive�, Inc. Investor Morning - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1.05% 1.02%
Operating margin 8.59% 4.83%
EBITD margin - 14.04%
Return on average assets -0.63% 0.60%
Return on average equity -1.18% 1.39%
Employees 1,358 -
CDP Score - -

Address

7475 Lusk Blvd.
SAN DIEGO, CA 92121
United States - Map
+1-858-9091800 (Phone)
+1-800-4759134 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NuVasive, Inc. is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is product portfolio is focused on applications for spine fusion surgery, including biologics. Its principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery (MAS). The product platform includes its software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and Intra-Operative Monitoring (IOM) support; MaXcess, an integrated split-blade retractor system, and a variety of specialized implants. Its biologic product line offerings used to aid the spinal fusion process or bone healing include allograft (donated human tissue), Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells, or MSCs, FormaGraft, a collagen synthetic product, and AttraX, a synthetic bone graft material.

Officers and directors

Alexis V. Lukianov Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Keith C. Valentine President, Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Quentin S Blackford Chief Financial Officer, Chief Accounting Officer
Age: 35
Bio & Compensation  - Reuters
Patrick W. G. Miles President, Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Jason M. Hannon Executive Vice President - Corporate Development, General Counsel, Secretary
Age: 42
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Link Executive Vice President - U.S. Sales
Age: 39
Bio & Compensation  - Reuters
Mike Paolucci Executive Vice President - Global Human Resources
Age: 54
Bio & Compensation  - Reuters
Carol Cox Executive Vice President - Strategy and Corporate Communications
Bio & Compensation  - Reuters
Russell A. Powers Executive Vice President - International
Age: 44
Bio & Compensation  - Reuters
Jack R. Blair Independent Director
Age: 71
Bio & Compensation  - Reuters